eyecro data to be presented at ARVO 2016 in Seattle

EyeCRO recently requested and conducted a pre-IND meeting with the US FDA to discuss the nonclinical and clinical development plans for CsA-MiDROPS™ to treat Dry Eye Disease. The agency was supportive of the project and agreed that the proposed nonclinical and CMC studies would allow entry into a phase II clinical trial. Also discussed was…

Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization Click here to read more

“Toward enhancing ethical practices in scientific research, EyeCRO has joined several industry-leading companies to sign the “Marseille Declaration”, the first joint pharmaceutical industry declaration on animal housing and use.” Click here to read the full press release

EyeCRO scientist Jarrod Harman contributed to a paper focused on X-linked juvenile retinoschisis published in Experimental Eye Research. This paper expands the mechanistic understanding of XLRS. Read the full paper here https://www.sciencedirect.com/science/article/pii/S0014483523002129?dgcid=coauthor

EyeCRO will be attending the 2026 ARVO Annual Meeting in Denver, Colorado, May 3-7. ARVO brings together over 11,000 eye and vision researchers from 75 countries, and it remains the most important meeting in our field for sharing new findings and building collaborations. This year’s theme focuses on how innovative vision research is driving the…

EyeCRO is thrilled to announce the first clinical application of our groundbreaking MiDROPS® technology.